These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 22573655

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Cost analysis comparing adjuvant epimacular brachytherapy with anti-VEGF monotherapy for the management of neovascular age-related macular degeneration.
    Jackson TL, Kirkpatrick L, Tang G, Prasad S.
    Eye (Lond); 2012 Apr; 26(4):557-63. PubMed ID: 22261737
    [Abstract] [Full Text] [Related]

  • 26. A licence to cure.
    Aronson JK, Ferner RE.
    BMJ; 2015 Apr 01; 350():h1723. PubMed ID: 25834026
    [No Abstract] [Full Text] [Related]

  • 27. GMC is criticised for refusing to disclose reasons behind its advice to support prescribing for Lucentis rather than Avastin for wet AMD.
    Cohen D.
    BMJ; 2015 Apr 13; 350():h1981. PubMed ID: 25869865
    [No Abstract] [Full Text] [Related]

  • 28. Response to Replacing ranibizumab with bevacizumab on the Pharmaceutical Benefits Scheme: where does the current evidence leave us?
    O'Shea JG.
    Clin Exp Optom; 2012 Sep 13; 95(5):541-3. PubMed ID: 22672003
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Macular degeneration, patients' groups, and pharma.
    The Lancet.
    Lancet; 2007 Jul 21; 370(9583):194. PubMed ID: 17658373
    [No Abstract] [Full Text] [Related]

  • 31. Modelling cost effectiveness in neovascular age-related macular degeneration: the impact of using contrast sensitivity vs. visual acuity.
    Butt T, Patel PJ, Tufail A, Rubin GS.
    Appl Health Econ Health Policy; 2014 Jun 21; 12(3):289-97. PubMed ID: 24610632
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Cancer drug offers effective, cheaper option for AMD.
    Stephenson J.
    JAMA; 2011 May 25; 305(20):2053-4. PubMed ID: 21610231
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Implications of "not me" drugs for health systems: lessons from age related macular degeneration.
    Campbell RJ, Dhalla IA, Gill SS, Bell CM.
    BMJ; 2012 May 01; 344():e2941. PubMed ID: 22549055
    [No Abstract] [Full Text] [Related]

  • 40. [Vision for patients with macular degeneration].
    Paukstadt W.
    MMW Fortschr Med; 2007 Jan 18; 149(3):10-2. PubMed ID: 17619375
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.